Agios Pharmaceuticals (NASDAQ:AGIO) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a sell rating to a hold rating in a research report report published on Sunday morning.

Other equities research analysts have also recently issued research reports about the stock. Leerink Partners upped their price objective on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, December 29th. Citigroup boosted their price target on Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Bank of America upped their price target on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Finally, HC Wainwright raised their price objective on Agios Pharmaceuticals from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $40.67.

Agios Pharmaceuticals Stock Down 0.2%

Shares of AGIO stock opened at $27.86 on Friday. The business’s fifty day moving average is $28.17 and its 200 day moving average is $32.49. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -3.92 and a beta of 0.89. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00.

Insider Transactions at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,932 shares of the business’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the chief financial officer directly owned 37,394 shares of the company’s stock, valued at $1,013,003.46. The trade was a 7.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Krishnan Viswanadhan sold 2,959 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $27.80, for a total transaction of $82,260.20. Following the sale, the insider owned 5,141 shares of the company’s stock, valued at approximately $142,919.80. This represents a 36.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 36,262 shares of company stock valued at $984,237. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP raised its stake in shares of Agios Pharmaceuticals by 31.4% in the second quarter. Marshall Wace LLP now owns 684,669 shares of the biopharmaceutical company’s stock worth $22,772,000 after buying an additional 163,796 shares during the period. Assenagon Asset Management S.A. purchased a new position in Agios Pharmaceuticals during the third quarter valued at approximately $2,696,000. HighVista Strategies LLC lifted its holdings in Agios Pharmaceuticals by 178.5% during the third quarter. HighVista Strategies LLC now owns 195,298 shares of the biopharmaceutical company’s stock valued at $7,839,000 after purchasing an additional 125,171 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its position in shares of Agios Pharmaceuticals by 19.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company’s stock worth $42,565,000 after purchasing an additional 209,900 shares during the period. Finally, Boothbay Fund Management LLC boosted its position in shares of Agios Pharmaceuticals by 71.1% in the second quarter. Boothbay Fund Management LLC now owns 447,019 shares of the biopharmaceutical company’s stock worth $14,868,000 after purchasing an additional 185,798 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.